Zobrazeno 1 - 10 of 38 pro vyhledávání: '"S. G. Arbuck"'
2
Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial
Autor: S G Arbuck, Robert J. Mayer, R Gonin, James A. DeCaprio
Publikováno v: Journal of Clinical Oncology. 9:2128-2133
Forty-two previously untreated patients with advanced, measurable adenocarcinoma of the pancreas were treated with weekly fluorouracil (5-FU; 600 mg/m2 intravenous [IV]) and leucovorin 500 mg/m2 IV for 6 weeks followed by a 2-week rest. A median of 1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ed83ec363a0aff0bc7aa3ec2261dfbc
https://doi.org/10.1200/jco.1991.9.12.2128
Zobrazit plný text záznamu
3
Interleukin-2 Lymphokine-Activated Killer Cell Therapy of Non-Hodgkinʼs Lymphoma and Hodgkinʼs Disease
Autor: Z. P. Bernstein, L. Vaickus, N. Friedman, M. H. Goldrosen, H. Watanabe, R. Rahman, S. G. Arbuck, J. Sweeney, D. Vesper, E. D. Henderson, J. Zeffren, R. A. Dennin, D. Levitt, K. A. Foon
Publikováno v: Journal of Immunotherapy. 10:141-146
We conducted a phase II study utilizing interleukin-2 (IL-2) with lymphokine-activated killer (LAK) cells as therapy for non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). IL-2 was given at a fixed dose of 3 x 10(6) U/m2/day administered as a 2
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3269a3df0a39215363780d3e78d19e9a
https://doi.org/10.1097/00002371-199104000-00008
Zobrazit plný text záznamu
5
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition
Autor: L, Dudkin, M B, Dilling, P J, Cheshire, F C, Harwood, M, Hollingshead, S G, Arbuck, R, Travis, E A, Sausville, P J, Houghton
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 7(6)
The rapamycin ester, CCI-779, potently inhibits cell growth in vitro, inhibits tumor growth in vivo, and is currently in Phase I clinical trials. To further understand the relationship between plasma systemic exposure and inhibition of the target Ser
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::98f694105e4db7dee6f8ed9880fc1f72
https://pubmed.ncbi.nlm.nih.gov/11410517
Zobrazit plný text záznamu
7
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
Autor: P, Therasse, S G, Arbuck, E A, Eisenhauer, J, Wanders, R S, Kaplan, L, Rubinstein, J, Verweij, M, Van Glabbeke, A T, van Oosterom, M C, Christian, S G, Gwyther
Publikováno v: Journal of the National Cancer Institute. 92(3)
Anticancer cytotoxic agents go through a process by which their antitumor activity-on the basis of the amount of tumor shrinkage they could generate-has been investigated. In the late 1970s, the International Union Against Cancer and the World Health
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1eea7b045b0279e37a90e4ceb7e8dec7
https://pubmed.ncbi.nlm.nih.gov/16478740
Zobrazit plný text záznamu
8
A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors
Autor: J L, Grem, J M, Sorensen, E, Cullen, C H, Takimoto, S M, Steinberg, A P, Chen, J M, Hamilton, S G, Arbuck, N, McAtee, D, Lawrence, B, Goldspiel, P G, Johnston, C J, Allegra
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 5(9)
The purpose of this study was to perform a Phase I trial of raltitrexed, a selective inhibitor of thymidylate synthase, and to determine the pharmacokinetic and toxicity profiles as a function of raltitrexed dose. Fifty patients with advanced solid t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::288f06bc6a5369531adcee7a27b4d164
https://pubmed.ncbi.nlm.nih.gov/10499608
Zobrazit plný text záznamu
9
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia
Autor: Francis J. Giles, M. Beran, Hai T. Tran, Bruce D. Cheson, Hagop M. Kantarjian, S. G. Arbuck, Jorge E. Cortes, Eli Estey, Carol Bivins, Norbert Vey, Susan O'Brien
Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 10(5)
Summary Purpose: Topoisomerase I inhibitors have shown promising anti leukemic activity in acute myelogenous leukemia (AML) and myelodysplastic syndrome. In this phase I study, we investigated the toxicity profile, pharmacokinetics, and activity of a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::489c9d283b988c44c8351fede0f5c303
https://pubmed.ncbi.nlm.nih.gov/10416008
Zobrazit plný text záznamu
10
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein
Autor: E, Fuse, H, Tanii, N, Kurata, H, Kobayashi, Y, Shimada, T, Tamura, Y, Sasaki, Y, Tanigawara, R D, Lush, D, Headlee, W D, Figg, S G, Arbuck, A M, Senderowicz, E A, Sausville, S, Akinaga, T, Kuwabara, S, Kobayashi
Publikováno v: Cancer research. 58(15)
The pharmacokinetics of UCN-01 after administration as a 72- or 3-h infusion to cancer patients in initial Phase I trials displayed distinctive features that could not have been predicted from preclinical data. The distribution volumes (0.0796-0.158
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::febaa155dc0416e0cb3ac37428d90688
https://pubmed.ncbi.nlm.nih.gov/9699650
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje